Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.50    -1.00 (-2.70%)
Bid:
35.00
Ask:
37.00
Spread: 2.00 (5.714%)
Market Cap: £16.76m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Holding(s) in Company

12 Aug 2024 12:15

RNS Number : 1162A
Cambridge Cognition Holdings PLC
12 August 2024
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Cambridge Cognition Holdings Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii: Change in total voting rights of issuer.

X

3. Details of person subject to the notification obligation

Name

NIGEL WRAY

City and country of registered office (if applicable)

LONDON, U.K.

4. Full name of shareholder(s) (if different from 3.) v

Name

GLOBAL PRIME PARTNERS

HSBC GLOBAL CUSTODY NOMINEE (UK) LTD

City and country of registered office (if applicable)

LONDON, U.K.

5. Date on which the threshold was crossed or reached:

26/07/2024

6. Date on which issuer notified (DD/MM/YYYY):

30/07/2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

11.9850 %

11.9850 %

5,026,547

Position of previous notification (if

applicable)

12.9527 %

12.9527 %

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORDINARY SHARES GB00B8DV9647

5,026,547

11.9850 %

SUBTOTAL 8. A

5,026,547

11.9850 %

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdate

Exercise/Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdate

Exercise/Conversion Period xi

Physical or cash

settlement

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Nigel Wray has a beneficial interest in shares held by

HSBC GLOBAL CUSTODY NOMINEE (UK) LTD

GLOBAL PRIME PARTNERS

 

11.9850 %

11.9850 %

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional information 

Of the shares in 8 above, 314,000 shares are held as a Trustee of The Priory Foundation, a charitable trust in which I have no beneficial interest.

 

 

 

Place of completion

London

Date of completion

30/07/2024

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLPTMBTMTBBBJI
Date   Source Headline
1st Jun 20267:00 amRNS-RCOG to present at Mello 2026
28th May 20261:15 pmRNSLaunch of brain health study with Oura
21st May 20262:50 pmRNSResult of AGM
24th Apr 20263:16 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSResults for the year ended 31 December 2025
7th Apr 20267:01 amRNSNotice of Results
7th Apr 20267:00 amRNSAppointment of Nominated Adviser and Joint Broker
1st Apr 20267:00 amRNSBlock Listing Return
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
16th Feb 20267:00 amRNSCommercialisation Agreement
9th Feb 20267:00 amRNSChange of Joint Broker
19th Jan 20267:00 amRNSTrading Update
5th Nov 20257:01 amRNSChange of Auditor
5th Nov 20257:00 amRNSBoard Updates
1st Oct 20257:00 amRNSBlock Listing Return
29th Sep 20257:00 amRNSExercise of Options and Total Voting Rights
26th Sep 20259:59 amRNSHolding(s) in Company
8th Sep 20257:00 amRNSHolding(s) in Company
5th Sep 20252:51 pmRNSHolding(s) in Company
5th Sep 202512:04 pmRNSHolding(s) in Company
2nd Sep 20255:21 pmRNSHolding(s) in Company
1st Sep 202510:58 amRNS-RInvestor Presentation via Investor Meet Company
28th Aug 202510:45 amRNS£1.12m Placing & Subscription, TVR & PDMR Dealings
28th Aug 20257:01 amRNSChanges to Board and Management
28th Aug 20257:00 amRNSInterim Results
19th Aug 202510:10 amRNS-RMonument Therapeutics Partnership with FNIH
12th Aug 20257:00 amRNSLaunch of Speaker Identification Solution
31st Jul 20257:00 amRNSTrading update for period ended 30 June 2025
27th Jun 202512:27 pmRNSResult of AGM
24th Jun 20257:00 amRNS-RMonument Therapeutics Success in Phase I Results
4th Jun 20257:00 amRNSNotice of AGM
6th May 20255:59 pmRNSHolding(s) in Company
1st May 20257:00 amRNSPreliminary Unaudited Results
24th Apr 20257:00 amRNSNotice of Results and Investor Presentation
10th Apr 20257:00 amRNSContract Win
7th Apr 202510:24 amRNSHolding(s) in Company
3rd Apr 20257:00 amRNSContract Win
1st Apr 20257:00 amRNSBlock Listing Return
6th Mar 20257:00 amRNS-RCANTAB® used for major global brain health study
18th Feb 20257:00 amRNS-RCambridge Cognition submits FDA Letter of Intent
7th Feb 20257:00 amRNSBoard Appointment
21st Jan 20257:00 amRNSLaunch of in-house rater training service
16th Jan 20257:00 amRNSExpanded partnership with Actinogen
27th Dec 20243:34 pmRNSDirector/PDMR Share Purchases
23rd Dec 20244:02 pmRNSDirector/PDMR Share Purchases
16th Dec 20249:20 amRNSDirector/PDMR Share Purchases
10th Dec 20247:00 amRNSTrading Update
18th Nov 20244:02 pmRNSHolding(s) in Company
6th Nov 20247:00 amRNSMonument Therapeutics secures £1m investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.